70915
当前位置: 首页   >  课题组新闻   >  Dr. Hideki Taniguchi, a famous international expert in regenerative medicine, appointed as a visiting professor in our university-国际著名再生医学专家谷口英树博士受聘我校客座教授
Dr. Hideki Taniguchi, a famous international expert in regenerative medicine, appointed as a visiting professor in our university-国际著名再生医学专家谷口英树博士受聘我校客座教授
发布时间:2019-09-16

       2019年 4月30日,应江苏大学及再生医学研究院(筹)邀请,日本东京大学谷口英树(TANIGUCHI, Hideki)教授一行来我校访问,并受聘为我校客座教授。聘任仪式在我校附属医院门诊六楼会议室举行,副校长全力、药学院院长徐希明、日本筑波大学郑允文教授、附属医院在院领导及我校医学院、药学院50多位师生参加仪式,附属医院副院长李遇梅主持会议。

  谷口教授现为东京大学医科学研究所干细胞治疗研究中心主任、再生医学研究分野教授。聘任仪式上,附属医院陈德玉院长介绍了我国目前干细胞及再生医学方面的研究情况,全力副校长为谷口英树教授颁发聘书并佩戴校徽,对谷口英树教授受聘及同我校的相关合作给予高度期望及关心,希望通过紧密合作,联合江苏大学医学院、药学院和日本东京大学、筑波大学等海内外合作院校,打造基础干细胞研究与再生医学应用以及肿瘤免疫治疗紧密结合的医学类研究的新模式。

  聘任仪式结束后,谷口英树教授为广大师生做了题为“诱导多能性干细胞(iPSC)由来类器官的肝疾患再生移植治疗技术的开发”的精彩讲座。讲座围绕iPS细胞由来的肝脏类器官展开,介绍了干细胞与再生医学领域的最新进展,为师生们提供一场学科盛宴。教授还与我校师生们进行了热烈的学术讨论,并对年轻一代的科研工作者们提出了宝贵的建议。

  谷口英树教授从事肝脏外科及再生医学研究30年,特别是在诱导多能性干细胞(iPSC)的肝脏再生医学与类器官移植治疗研究方面取得重要突破,成为日本乃至世界肝脏再生移植研究的领军人物,为日本iPS细胞在肝脏疾患治疗研究领域的首席科学家,2014年因此成就获德国贝尔兹奖(Erwin von Baelz)。现已发表SCI论文150余篇,并多次刊登在高影响力杂志上,如Nature, Nature Medicine, Nature Protocol, Cell Stem Cells, Cell Reports, Stem Cell Reports, PNAS, JCI, JCB, Gastroenterology, Hepatology, J Hepatology等。出版日英文书籍35章节,日文综述178篇,获专利授权19项。据不完全统计,从日本文部省,日本学术振兴学会,日本科学技术振兴机构,日本医疗研究开发机构,日本厚生劳动省等各级研究机构获得资助约122项,计22.2亿日元(约1.35亿元人民币)。

      On April 30th, 2019, at the invitation of Jiangsu University and Institute of Regenerative Medicine, Professor TANIGUCHI,Hideki of the University of Tokyo visited our university and was appointed as a visiting professor of our university. The appointment ceremony was held in the conference room on the sixth floor of the outpatient clinic of the affiliated hospital of our university. vice president Quan Li, dean of the School of Pharmacy Xu Ximing, Professor Zheng Yunwen of the University of Tsukuba, Japan, leaders of the affiliated hospital and more than 50 teachers and students of the School of Medicine and Pharmacy of our university attended the ceremony. Li Yumei, vice president of the affiliated hospital, presided over the meeting.

     Professor Taniguchi is currently the director of the Stem Cell Therapy Research Center of the Institute of Medical Sciences of the University of Tokyo and a professor of regenerative medicine research. At the appointment ceremony, the dean of the affiliated hospital, Chen Deyu, introduced the current research on stem cells and regenerative medicine in China, and the vice president issued a letter of appointment and wore a school badge for Professor Taniguchi. He is highly expected and concerned about Professor Taniguchi's employment and relevant cooperation with our university. Through close cooperation, we will work closely with Jiangsu University School of Medicine, Tokyo University, Tsukuba University and other cooperative universities at home and abroad. To create a new model of medical research that combines basic stem cell research with the application of regenerative medicine and tumor immunotherapy. 

    After the appointment ceremony, Professor Hideki Taniguchi gave a wonderful lecture entitled "Development of regenerative transplantation techniques for inducing pluripotent stem cell (iPSC) derived organs for liver diseases" for teachers and students. The lecture focuses on the liver-like organs derived from iPS cells, introduces the latest progress in the field of stem cells and regenerative medicine, and provides a feast for teachers and students. The professor also had a heated academic discussion with the teachers and students of our school, and put forward valuable suggestions to the younger generation of researchers. 

     Professor Taniguchi has been engaged in liver surgery and regenerative medicine for 30 years, especially in liver regenerative medicine and organ-like transplantation treatment of induced pluripotent stem cell (iPSC). He has become a leader in liver regenerative transplantation research in Japan and even in the world, and is the chief scientist in the field of liver disease treatment of iPS cells in Japan. For this reason, he won the German Beltz Prize (ErwinvonBaelz) in 2014. More than 150 SCI papers have been published, and have been published in high-impact magazines, such asNature,Nature Medicine,Nature Protocol, Cell Stem Cells,Cell Reports,Stem Cell Reports, PNAS, JCI ,JCB, Gastroenterology ,Hepatology, JHepatology, etc. On the day of publication, there are 35 chapters in English books, 178 reviews in Japanese and 19 patents granted. According to incomplete statistics, research institutions at all levels, such as the Ministry of Education of Japan, the Japanese Society for academic Revitalization, the Japanese Institute for the Promotion of Science and Technology, the Japanese Medical Research and Development Institute, and the Ministry of Health and Labor of Japan, have received funding of about 122. the total is 2.22 billion yen (about 135 million yuan).